[Experimental study on basic fibroblast growth factor combined slow-releasing degradable membrane to prevent tendon adhesion].
OBJECTIVE
To study the adhesion-preventing effect of basic fibroblast growth factor (bFGF) combined slow-releasing degradable membrane.


METHODS
The bFGF combined slow-releasing degradable membrane was made from bFGF and the reagent which could promote fibrinogen synthesize. Sixty-six SD rats were divided into groups A, B, C randomly (22 rats each group). In group A, sutured achilles tendon were encapsulated with bFGF combined slow-releasing degradable membrane; in group B, sutured achilles tendon were encapsulated with degradable membrane without any drug; in group C, achilles tendon were only sutured. Ninety days later, light-microscope, electron-microscopoe, figure-analysing, hydroxyproline content, extent of peritendon adhesion and biomechanic test were evaluated.


RESULTS
1. The amount of fibroblast and fibrinogen inside the sutured tendon in group A was larger than that in its peripheral connective tissue and in groups B and C (P < 0.05). The content of hydroxyproline and the ultimate tensile strength in group A was higher than those in groups B and C (P < 0.01). 2. The peripheral tissue in group A almost remains the formal loose connective tissue, but it became dense connective tissue in groups B and C and grew into the tendon. Moreover, the extent of adhesion in group A was lesser than that in groups B, C according to the mensuration of peritendon adhesion.


CONCLUSIONS
The bFGF combined slow-releasing degradable membrane can make the intrinsic healing of tendon faster than peripheral connective tissue proliferation, so it can prevent the formation of adhesion.
Sha
De-feng
DF
Department of Hand Surgery, Affiliated Central Hospital of Shenyang Medical College, Shenyang, Liaoning, P. R. China 110024.
Xin
Chang-tai
CT
Yang
Xiao-xia
XX
D000125:Achilles Tendon / Q000293:injuries* / Q000601:surgery / Q000648:ultrastructure; D000818:Animals; D003692:Delayed-Action Preparations; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage* / Q000494:pharmacology; D005347:Fibroblasts / Q000502:physiology*; D006909:Hydroxyproline / Q000032:analysis; D008297:Male; D008567:Membranes, Artificial; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013718:Tensile Strength; D000267:Tissue Adhesions / Q000517:prevention & control; D014945:Wound Healing / Q000187:drug effects*
D003692:Delayed-Action Preparations; D008567:Membranes, Artificial; D016222:Fibroblast Growth Factor 2; D006909:Hydroxyproline